tob is a member of an antiproliferative gene family that includes btg1, pc3/tis21/btg2, pc3b, ana/btg3, and tob2. Exogenous overexpression of the family proteins suppresses cell proliferation. These proteins participate in transcriptional regulation of several genes. Here, we show that Tob is a nuclear protein that is imported into the nucleus through a nuclear localization signal (NLS)-mediated mechanism. Mutation in the NLS sequence of Tob affects its nuclear localization and impairs antiproliferative activity. Additionally, Tob contains a nuclear export signal (NES). In oncogenic ErbB2-transformed cells, nuclear export of Tob is facilitated by NESmediated mechanism, resulting in decrease of its antiproliferative activity. These results indicate that regulation of nuclear localization of Tob is important for its antiproliferative activity.
Introduction
In higher eukaryotes, cell proliferation is regulated by extra-and intracellular signals. These signals lead to activation of cyclin-dependent protein kinases (CDKs), which are important for cell cycle progression (Morgan, 1995) . Growth stimulation signals, such as growth factors, cytokines, and antigens, cause cells to progress from the quiescent state to the G1/S transition. In many cases, the receptors for growth factors are associated with protein-tyrosine kinase (PTK) activity that is intrinsic to the receptors or receptor-associated proteins. Upon receptor stimulation, PTKs are activated, and then signals generated by PTKs at the inner surface of the cell membrane activate downstream molecules such as Ras, MAP kinase, PI3-kinase, and phospholipase Cg. Many of these signals are then transmitted to the nucleus to regulate gene expression (Marshall and Leevers, 1995) .
In our previous study on ErbB2 PTK signaling, we identified a growth regulatory protein, Tob, that belongs to the Tob/BTG antiproliferative protein family (Matsuda et al., 1996) . This family in human consists of six members: BTG1, BTG2, PC3B, Tob, Tob2, and ANA/ BTG3 (Rouault et al., 1992 (Rouault et al., , 1996 Guehenneux et al., 1997; Yoshida et al., 1998; Ikematsu et al., 1999; Buanne et al., 2000) . The amino-terminal 120 amino acids of these proteins show significant homology, therefore this region is designated as the Tob/BTG homology domain. Within the domain, there are two highly conserved regions, the A box and B box (Guehenneux et al., 1997; Guardavaccaro et al., 2000; Tirone, 2001) , corresponding, respectively, to amino-acid residues 40-58 and 86-105 of Tob. All members of the Tob/BTG family suppress cell growth when overexpressed exogenously in NIH3T3 cells (Matsuda et al., 1996; Montagnoli et al., 1996; Rouault et al., 1996; Yoshida et al., 1998; Ikematsu et al., 1999; Buanne et al., 2000; Suzuki et al., 2002) . BTG1 and BTG2 associate with the homeodomain-containing transcription factor Hoxb9 (Prevot et al., 2000) . All Tob/BTG family proteins are associated with CCR4-associated factor 1 (Caf1), which is a component of the CCR4-NOT transcription complex (Bogdan et al., 1998; Rouault et al., 1998; Ikematsu et al., 1999; Yoshida et al., 2000) . We recently reported that Tob is a negative regulator of BMP/Smad signaling in osteoblasts and that Tob regulates Smad-mediated transcription in a BMP2-dependent manner (Yoshida et al., 2000) . Moreover, exogenously expressed PC3, a rat homologue of BTG2, and Tob downregulate cyclin D1 transcription, resulting in suppression of G1 progression (Guardavaccaro et al., 2000; Yoshida et al., 2003) . These findings suggest that Tob/BTG family proteins interact with transcription factors directly or indirectly and that they participate in regulation of gene expression.
The importance of nuclear localization of Tob/BTG proteins was recently reported. BTG1 is localized in the nucleus of confluent avian myoblast QM7 cells, whereas it is localized in the cytoplasm diffusely in proliferating QM7 cell (Marchal et al., 1995; Rodier et al., 1999) . Moreover, triiodothyronine (T3) or 8-Br-cAMP treatment of QM7 cells induces nuclear accumulation of BTG1, which is accompanied by reduction of proliferation and stimulation of differentiation of QM7 cells (Marchal et al., 1993 (Marchal et al., , 1995 . The B box and the carboxyl-terminal domain of BTG1 (amino-acid positions 117-171) are responsible for the nuclear localization of BTG1 (Rodier et al., 2001) . However, it remains elusive as to how these sequences are involved in regulation of nucleus-cytoplasm trafficking of BTG1.
Here, we show that Tob is a nuclear protein and that nuclear localization of Tob is regulated via the bipartite nuclear localization signal (NLS). Mutations in these sequences result in distribution of Tob in the cytoplasm and impairment of the antiproliferative activity. We also show that Tob contains a nuclear export signal (NES). An NES mutant that is defective in nuclear export retains the antiproliferative activity. Thus, nuclear localization of Tob appears to be relevant to its antiproliferative activity.
Results

Nuclear localization of Tob protein
We showed previously that Tob is associated with transcriptional regulators, such as Caf1 and Smads (Ikematsu et al., 1999; Yoshida et al., 2000) . Tob regulates Smad-mediated transcription in a BMP2-dependent manner, suggesting that nuclear localization of Tob may be important for its function. To examine nuclear localization of Tob, we performed immunofluorescence staining experiments. As endogenous Tob was poorly detectable by our anti-Tob antibodies in immunostaining experiments, we analysed the subcellular distribution of Tob exogenously expressed in normal rat kidney (NRK) cells. NRK cells were infected with adenovirus containing the tob cDNA (Adex-Tob) or the b-galactosidase cDNA (Adex-b-Gal), and the subcellular distribution of each protein was examined by immunostaining with anti-Tob or anti-b-galactosidase antibody. As shown in Figure 1A , Tob was concentrated in the nucleus, whereas b-galactosidase (LacZ) was localized in the cytoplasm. To confirm the subcellular localization of endogenous Tob, we performed subcellular fractionation of NRK cells and detected the endogenous Tob by immunoblotting with anti-Tob antibody. Endogenous Tob was mostly present in the nuclear fraction, and was detected only at very low levels in the cytosolic fraction ( Figure 1B) . In monitoring the efficiency of fractionation, we detected CBP only in the nuclear fraction and Raf-1 only in the cytosolic fraction. These results indicated that Tob is localized mainly in the nucleus of NRK cells.
To dissect the biological significance of nuclear localization of Tob, we chose NIH3T3 cells for further study. To confirm that subcellular localization of Tob in NIH3T3 cells is virtually identical to that in NRK cells, we transfected the pME-Tob expression plasmid carrying the full-length tob cDNA into NIH3T3 cells. Immunostaining of the transfectants revealed that Tob was localized in the nucleus of more than 50% of cells ( Figure 1C, ÀWGA) . Thus, we assumed that subcellular localization of Tob is regulated similarly in NIH3T3 cells and in NRK cells. We then examined the effect of a nuclear transport inhibitor, wheat germ agglutinin (WGA), on localization of Tob. As shown in Figure 1C , the nuclear transport of Tob was inhibited by WGA ( þ WGA), indicating that nuclear localization of Tob is regulated by the classical NLS-mediated mechanism.
Tob contains a functional bipartite NLS
Among the Tob/BTG family proteins, only Tob and Tob2 contain the sequence that matches the consensus sequence of bipartite NLS (Jans and Hubner, 1996) adjacent to the A box (Matsuda et al., 1996; Ikematsu et al., 1999) . As nuclear localization of Tob is mediated through the classical NLS-mediated mechanism ( Figure 1C ), we hypothesized that the putative NLS (NLS22-39) regulates Tob nuclear localization. To confirm this, we fused the putative NLS to Figure 1D ). As the EGFP-b-Gal tag is too large (about 190 kDa) to diffuse passively into the nucleus, the fusion can reveal whether the NLS is functional (Bear et al., 1999; Luo and Shibuya, 2001 ). The EGFP-b-Gal tag alone was localized exclusively to the cytoplasm ( Figure 1D, a) . In contrast, the fusion protein with the putative Tob NLS (EGFP-WTNLS-b-Gal) showed complete nuclear localization ( Figure 1D, b) . We then introduced Arg to Gln substitution mutations at amino-acid positions 22-24 and Lys to Asn substitution mutations at amino-acid positions 37-39. Upon transfection of the resulted construct (pEGFP-QNNLS-b-Gal), the mutant protein, EGFP-QNNLS-b-Gal, localized exclusively in the cytoplasm ( Figure 1D , c). These results indicate that the putative NLS of Tob is functional.
To confirm that the nuclear localization of Tob protein is mediated through NLS22-39, we constructed an expression plasmid carrying the full-length tob cDNA containing the QN mutation (TobQN). We also constructed two additional NLS mutants: TobRQ (Gln substituted for Arg at amino-acid positions 22-24) and TobKN (Asn substituted for Lys at amino-acid positions 37-39) ( Figure 2A ). Wild-type Tob, Tob mutants, and b-Gal expression plasmids were transfected into NIH3T3 cells. The representative immunostaining data are shown in Figure 2B . In 53.5% of cells, exogenously expressed wild-type Tob was concentrated in the nucleus ( Figure 2B , b, and graph). TobRQ and TobKN proteins were not concentrated in the nucleus ( Figure 2B , d and e); TobRQ was distributed throughout the cell, and TobKN distributed in spots at the outer periphery of nucleus in the majority of cells. TobQN was localized exclusively in cytoplasm (85.9% of TobQN expressed cells, Figure 2B , c and graph). These data indicate that the NLS at amino-acid positions 22-39 of Tob is important for its nuclear localization.
Subcellular localization of Tob changes depending on cell cycle progression
We observed that Tob was present in the cytoplasm or distributed throughout the cells in 12.4. or 33.9%, respectively, of wild-type Tob expressing cells (see NoC or N ¼ C in Figure 2B graph). The data suggest that subcellular localization of Tob changes depending on cell growth states. Indeed, when cells were cultured in the serum-depleted medium for 48 h and arrested at G0 phase, Tob was mainly localized in the nucleus ( Figure 3A , 0 h). Until 1 h after serum-stimulation (early G1 phase), most of Tob proteins were localized in the nucleus. When the cells moved to the late S phase ( Figure 3A , 18 h), more than half of Tob proteins was detected in the cytosolic fraction. These data indicated that the subcellular distribution of Tob changes during the cell cycle. The detailed mechanism that regulates subcellular localization of Tob remains to be investigated. Interestingly, when we transfected Tob expression plasmid into NIH3T3 cells transformed by activated tyrosine kinases, such as ErbB2 and v-Src, cytosolic localization of Tob was greatly increased (N ¼ C þ NoC is 44.8% in NIH3T3 and 77.9% in ErbB2/NIH3T3). The representative data are shown in Figure 3B .
Tob contains two consensus sequences of NES
To examine whether Tob is exported from the nucleus, we tested the effect of leptomycin B (LMB) (Wolff et al., 1997) , which interferes with binding of the leucine-rich Rev-type NES to the export receptor exportin 1 (Fornerod et al., 1997; Fukuda et al., 1997; OssarehNazari et al., 1997) , on subcellular localization of Tob. pME-Tob was transfected into NIH3T3 cells, and cells were treated with LMB. In comparison with untreated cells, the proportion of Tob localized to the nucleus was increased in LMB-treated cells (50.7 vs 81.2%, data not shown). These data suggest the existence of leucine-rich Rev-type NES in the amino-acid sequence of Tob. Two regions, amino-acid positions 82-92 (NES82-92) and [226] [227] [228] [229] [230] [231] [232] [233] [234] in Tob, showed significant similarity to the previously identified NES sequences (NES consensus sequence is Lx (1-3) Lx (2-3) LxL; L is changeable with hydrophobic residues and x indicates any residues (Wen et al., 1995; Fukuda et al., 1996) ; Figure 4A ). In addition, there is a report that the sequence in BTG1 that corresponds to the amino acids 82-92 of Tob serves for its nuclear export (Rodier et al., 2001) . To determine whether nuclear export of Tob is mediated through these putative NESs, we mutated the leucine residues of Tob (Leu90 and Val 92, or Leu232 and Leu234) that were thought to be critical for the NES function (Fischer et al., 1995; Gorlich and Mattaj, 1996; Nigg, 1997) ( Figure 4A ). The expression plasmids pMETobL90A/V92A (TobLAVA) and pME-TobL232A/ L234A (TobLALA), which encode the mutated proteins, were then transfected into NIH3T3 cells. Immunostaining of the transfectants with anti-Tob antibody revealed that TobLALA was not exported to the cytoplasm ( Figure 4B , b and C), suggesting that NES226-234 functions as leucine-rich Rev type NES. Unexpectedly, TobLAVA, like TobQN, was hardly imported to the nucleus ( Figure 4B , d and C). This finding suggested that NES82-92 may virtually function as NLS. Then, to assess whether the NES82-92 functions as NLS, we fused it to EGFP-b-Gal and examined subcellular distribution of the fusion protein in NIH3T3 cells. In contrast to the WT NLS (NLS22-39) fusion protein ( Figure 5A, b) , the NES82-92 fusion protein was not transported into the nucleus ( Figure 5A , c) These results suggest that NES82-92 is important for nuclear localization of Tob but does not function as a bona fide NLS.
NES82-92 and NES226-234 possess weak NES activity
We examined whether NES82-92 and NES226-234, respectively, act as NES by using pRev(1.4)-GFP expression vector ( Figure 5B ) (Henderson and Percipalle, 1997; Henderson and Eleftheriou, 2000) . Rev carries both NLS and NES (Kubota et al., 1989; Meyer and Malim, 1994) . Since the NES is mutated in Rev(1.4), Rev(1.4)-GFP fusion protein accumulates in the nucleus (Henderson and Percipalle, 1997) . Insertion of a functional NES between Rev(1.4) and GFP enables the fusion protein to be exported to cytoplasm. Moreover, the Rev NLS can be inactivated by treating cells with actinomycin D, which allows detection of the activity of very weak NESs (Henderson and Eleftheriou, Figure 5C and Table 1) . After 3 h treatment with actinomycin D, the subcellular distribution of Rev(1.4)-GFP was not changed, while the proportion of cytoplasmic Rev(1.4)-RevNES-GFP was slightly increased. When Rev(1.4)-NES226-234-GFP was expressed in NIH3T3 cells, GFP signals were detected throughout the cell (N þ C) in 18.3% of the fusion protein-expressing cells. Actinomycin D treatment raised the proportion of cytoplasmic Rev(1.4)-NES226-234-GFP ( Figure 5C and Table 1 , N þ C: 49.9%). Similar results were obtained in case of the Rev(1.4)-NES82-92-GFP protein ( Figure 5C and Table 1 ). According to the NES scoring system that was proposed by Henderson and Eleftheriou (2000) , NES activities of NES226-234 and NES82-92 both correspond to 1 þ , whereas the Rev NES activity corresponds to 9 þ in NIH3T3 cells ( Figure 5C and Table 1 ). These results suggest that NES226-234 and NES82-92 contain NES activity that is as low as that of the p53 protein (Henderson and Eleftheriou, 2000) , and confirm that NES82-92 and NES226-234 of Tob are bona fide NESs. Although NES82-92 possesses weak NES activity, point mutations in this region impaired nuclear localization ( Figures 4C and 5C ). We assume that the Tob protein was structurally altered by the point mutations so that it simply became difficult to translocate into the nucleus. (See Discussion in detail.)
Nuclear export of Tob is facilitated in ErbB2-transformed cells
In ErbB2-transformed NIH3T3 cells, the proportion of Tob distributed to the cytoplasm was increased ( Figure 3A ). To examine whether this phenomenon is Figure 5 The function of NES82-92 and NES226-234. (A) NES82-92 sequence cannot act as NLS. Tob NES82-92 containing peptide was subcloned into the expression vector, which was described in Figure 1D due to inhibition of NLS-mediated nuclear import or due to facilitation of NES-mediated nuclear export, we analysed the localization of TobLALA (NES226-234 mutant) in ErbB2-transformed cells. Unlike WT-Tob, the proportion of TobLALA localized mostly in the nucleus in the ErbB2-transformed cells as in untransformed cells (Figure 4C and D) . The data suggest that Tob is exported to the cytoplasm through NESmediated mechanism when cell growth is extensively stimulated.
Correlation of Tob nuclear localization with antiproliferative activity
We previously showed that exogenously overexpressed Tob suppresses growth of NIH3T3 cells (Matsuda et al., 1996; Suzuki et al., 2002) . Here, we examined whether disruption of nuclear localization of Tob affects its antiproliferative activity. pME-Tob or pME-TobQN was microinjected into serum-starved NIH3T3 cells, and the number of cells that entered S phase were counted after serum stimulation. Whereas 71.2% cells microinjected with pME-b-Gal incorporated BrdU, only 18.6% cells microinjected with pME-Tob showed incorporation of BrdU (Po0.05; Figure 6 ). In contrast, the ability of the TobQN mutant to suppress cell growth was greatly impaired; 55.7% cells microinjected with the pME-TobQN plasmid incorporated BrdU. The data indicated that cytoplasmic Tob is poorly antiproliferative. In addition, the cells microinjected with the pMETobLALA (NES226-234 mutant) showed suppression of cell growth to an extent similar to cells expressing wild-type Tob. Importantly, the cell growth suppression by TobLAVA (NES82-92 mutant), which is not imported into the nucleus, was reduced. The degree of growth suppression by TobLAVA and TobQN may be reflecting their subcellular localization; the proportion of TobLAVA distributed throughout the cell (23.8%) was larger than that of TobQN (7.5%). These data indicate that nuclear localization of Tob is important for antiproliferative activity.
Discussion
Among the members of the Tob/BTG family of antiproliferative protein, only Tob and Tob2 contain a putative NLS at their N-termini (Matsuda et al., 1996; Ikematsu et al., 1999) . The putative NLS sequence of Tob, NLS22-39, is bipartite and similar to that of p53 (Liang and Clarke, 1999) . In the present study, we show that NLS22-39 is functional. NLS22-39 fused b-Gal protein is imported into the nucleus, whereas b-Gal alone is not, and Tob with mutation in NLS22-39 showed cytoplasmic localization ( Figures 1D and 2B ). Our data strongly suggest that the antiproliferative activity of Tob correlates with its nuclear localization ( Figure 6 ). BTG1 is also imported into the nucleus, and its nuclear localization is correlated with myogenic activity in myoblasts (Rodier et al., 2001) . These findings suggest that other Tob/BTG family members also function in the nucleus. Consistent with this idea, recent reports show that Tob and BTG1 associate with various transcription factors and transcriptional regulators such as Hoxb9 (Prevot et al., 2000) and Caf1 (Bogdan et al., 1998; Rouault et al., 1998; Ikematsu et al., 1999; Yoshida et al., 2000; Nakamura et al., 2004) . PSORT II (http:// psort.nibb.ac.jp/cgi-bin/runpsort.pl), a program that predicts subcellular localization sites of proteins on the basis of their amino-acid sequences, indicates that all the other family members show nuclear localization. Recent report suggested that the B box of BTG1 is relevant to its nuclear translocation (Rodier et al., 2001) . The B box is conserved among all the Tob/ BTG family proteins, suggesting the presence of common regulatory mechanism in the B box-mediated nuclear translocation. It is possible that only Tob and Tob2 among Tob/BTG family members contain a classical NLS because their molecular masses are larger than those of other family members. Adam et al (1989) reported that nuclear proteins with relative molecular masses larger 20 000-40 000 are probably transported actively into the nucleus through the nuclear pore complex due to a specific NLS. Since the molecular masses of Tob and Tob2 are 45 and 43 kDa, respectively, and those of the other family members are less than 30 kDa, specific sequences for nuclear localization may be necessary for Tob and Tob2 to be efficiently transported into the nucleus. We found that Tob contains two putative NES consensus sequences . Mutation experiments and nuclear export assays revealed that NES226-234 functions as NES in Tob protein (Figures 4C and 5C, and Table 1 ). Nuclear export assay suggested that NES82-92 also functions as NES ( Figure 5C ). This result is consistent with the finding that BTG1 NES is present in the region corresponding to Tob NES82-92 (Rodier et al., 2001) . Unexpectedly, TobLAVA, and another NES82-92 mutant, TobV82A showed subcellular localization pattern similar to the NLS mutant, TobQN ( Figure 4B , C and data not shown). A possible reason for these inconsistent results might be due to the overlap of NES82-92 with B box. As mentioned above, Rodier et al. (2001) showed that B box is relevant to BTG1 nuclear translocation by deletion analysis. However, direct assay of the NLS activity of NES82-92 revealed that it does not function as a bona fide NLS ( Figure 5A ). Importantly, our unpublished results on the X-ray crystallography of the Tob protein suggest that the B box, which overlaps with residues 82-92, and the surrounding sequence form a unique three-dimensional structure. It is likely that the LAVA mutation easily disrupt the structure, resulting in mislocalization of the mutant protein.
Although both Tob and BTG1 contain NES, the biological significance of nuclear export of the molecules remains unclear. One possibility is that the nuclear export may be important for rapid degradation of Tob/ BTG1 family proteins, whose half-life is very short (Sasajima et al., 2002) .
Our data suggest that subcellular localization of Tob changes depending on cell growth status because a proportion of wild-type Tob is localized in the cytoplasm in asynchronously growing cells ( Figure 2B ) and the proportion of cytoplasmic Tob is increased in oncogenic ErbB2-transformed NIH3T3 cells ( Figure 3B ). Indeed, we found that the distribution of endogenous Tob changed depending on the cell cycle ( Figure 3A) . Moreover, BTG1 is localized in the nuclei of confluent myoblasts and cytoplasmic BTG1 gradually increases during myotube formation and maturation (Marchal et al., 1993 (Marchal et al., , 1995 Rodier et al., 1999) . Taken together, these findings suggest that trafficking of Tob family proteins between the nucleus and cytoplasm may be important for regulation of cell cycle progression and differentiation.
In ErbB2-transformed cells, cytoplasmic Tob is remarkably increased (Figures 3B and 4D) . Despite the abundance of Tob protein in these cells, proliferation was not suppressed (Matsuda et al., 1996) , probably due to both cytoplasmic localization of Tob and facilitation of Tob phosphorylation, possibly in the nucleus, by Erk1/2 that is activated downstream of the ErbB2 receptor. Therefore, the antiproliferative activity of Tob appears to be regulated by two means: phosphorylation by Erk1/2 (Suzuki et al., 2002) and nuclear export. Similar results were obtained in oncogenic-Ras-and oncogenic-Src-tranformed cells (data not shown). These data implicate that impaired nuclear localization as well as facilitated phosphorylation of Tob is involved in oncogene-induced cellular transformation and tumorigenesis.
In conclusion, trafficking of Tob between the nucleus and the cytoplasm is mediated by NLS and NES, and nuclear localization of Tob is essential for its antiproliferative activity.
Materials and methods
Cells
NIH3T3 cells were grown in complete Dulbecco's modified Eagle medium (DMEM, Nissui) with 10% calf serum (CS). Rat normal kidney (NRK) cells were grown in complete DMEM with 10% fetal bovine serum (FBS). For inhibition of nuclear import by WGA (SIGMA L0636), cells were preincubated with 400 mg/ml WGA in the culture medium for 30 min at 371C before fixation. For inhibition of nuclear export by leptomycin B (LMB, kindly gift from Dr M Yoshida), cells were preincubated with 10 ng/ml LMB in the culture medium for 1 h at 371C before fixation.
Construction of plasmids and adenoviral vectors pME-Tob expression plasmid was previously described (Matsuda et al., 1996) . pME-TobRQ encoding QQQ substituted for RRR at amino-acid position 22-24 was generated by the method of Kunkel (Kunkel and Soni, 1988) . Similarly, pME-TobKN having NNN for KKK mutation at position 37-39, pME-TobQN having both RRR to QQQ mutation and KKK to NNN mutation, pME-TobL90A/V92A, and pMETobL232A/L234A were generated by the same method. To prepare an adenoviral vector for Tob expression, pCMVXwt1-Tob was constructed by cloning the EcoRI fragment of Tob cDNA and blunt ended into the SwaI site of cassette cosmid pAdex1pCAw. Recombinant adenovirus containing the tob cDNA (Adex-Tob) was obtained by cotransfection pCMVXwt1-Tob and EcoT221-digested Ad5-dlX into HEK293 cells (Miyake et al., 1996) . Adenovirus containing the b-galactosidase gene (Adex-b-Gal), cording for the bacterial enzyme b-galactosidase, was prepared as a control.
Transfection, adeno virus infection and microinjection
Cells were transfected using the Gene POTER transfection kit (Gene Therapy Systems) with 10 mg of plasmid DNA per dish and cultured for 2 days. NRK cells were infected with AdexTob or Adex-LacZ at m.o.i. 20. Cells were lysed at 48 h after infection and the expression of each protein was detected by Western blotting as previously described (Suzuki et al., 2002) . Microinjection was carried out as previously described (Ikematsu et al., 1999) .
Antibodies
Anti-Tob polyclonal antibody was previously described (Matsuda et al., 1996) , and anti-Tob monoclonal antibody 4B1 was from IBL (Japan). Anti-b-galactosidase polyclonal antibody was from 5 Prime-3 Prime, Inc. Anti-BrdU monoclonal antibody BU-4 was purchased from Takara (Japan), FITC-conjugated antibody raised against mouse IgG was from Sigma, FITC-conjugated antibody raised against rabbit IgG was from Southern Biotechnology Associates, Inc. and rhodamine-conjugated antibody raised against mouse IgG was from CHEMICON INTERNATIONAL INC. Anti-CBP (C-20) and anti-Raf-1 polyclonal antibodies were from Santa Cruz Biotechnology, Inc.
Immunofluorescence staining and cell fractionation
The cells were seeded on coverslips 24 h before transfection, microinjection or virus infection and were immunofluorescence stained as described (Ikematsu et al., 1999) . For cell fractionation, 6 Â 10 6 NRK cells were used. Cell fractionation was carried out as described previously (Dignam et al., 1983) .
